Acadia Pharms Inc Drug Patent Portfolio

Acadia Pharms Inc owns 2 orange book drugs protected by 24 US patents Given below is the list of Acadia Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11827600 Crystalline forms of trofinetide 12 Jul, 2042
Active
US11370755 Compositions of trofinetide 03 Aug, 2040
Active
US10449185 Formulations of pimavanserin 27 Aug, 2038
Active
US10646480 Formulations of pimavanserin 27 Aug, 2038
Active
US10849891 Formulations of pimavanserin 27 Aug, 2038
Active
US11452721 Formulations of pimavanserin 27 Aug, 2038
Active
US10517860 Combination of pimavanserin and cytochrome P450 modulators 23 Mar, 2037
Active
US10953000 Combination of pimavanserin and cytochrome P450 modulators 23 Mar, 2037
Active
US9212204 Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid 27 Jan, 2032
Active
US7601740 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 29 Apr, 2030
Active
US7732615 N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms 03 Jun, 2028
Active
US7659285 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 24 Aug, 2026
Active
US7923564 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms 26 Sep, 2025
Active
US10028944 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 15 Jan, 2024 Expired
US8618130 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 15 Jan, 2024 Expired
US8921393 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 15 Jan, 2024 Expired
US9566271 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 15 Jan, 2024 Expired
US9765053 Methods of treatment using selective 5-HT2A inverse agonists 27 Jul, 2022 Expired
US7115634 4-aminopiperidine and their use as a medicine 06 Oct, 2021 Expired
US6756393 Azacyclic compounds 06 Mar, 2021 Expired
US6815458 Azacyclic compounds 06 Mar, 2021 Expired
US9296694 Azacyclic compounds 06 Mar, 2021 Expired
US7858789 Derivatives of 4-aminopiperidine and their use as a medicament 13 Dec, 2020 Expired
US8110574 Derivatives of 4-aminopiperidine and their use as a medicament 13 Dec, 2020 Expired


Given below is the list of recent legal activities going on the following drug patents of Acadia Pharms Inc.

Activity Date Patent Number
Patent litigations
Electronic Review 07 Jun, 2024 US7601740
Payment of Maintenance Fee, 4th Year, Large Entity 03 Jun, 2024 US10849891
Email Notification 06 May, 2024 US7601740
Expire Patent 06 May, 2024 US9296694
Email Notification 02 May, 2024 US7601740
Mail O.P. Petition Decision 02 May, 2024 US7601740
Mail-Petition Decision - Dismissed 30 Apr, 2024 US7601740
O.P. Petition Decision 29 Apr, 2024 US7601740
Petition Decision - Dismissed 29 Apr, 2024 US7601740
Second letter to regulating agency to determine regulatory review period 03 Apr, 2024 US9212204
Petition Entered 15 Mar, 2024 US7601740
Expire Patent 11 Mar, 2024 US8110574
Letter from FDA or Dept of Agriculture re PTE application 24 Jan, 2024 US9212204
Email Notification 18 Jan, 2024 US7601740
Mail O.P. Petition Decision 18 Jan, 2024 US7601740


Acadia Pharms Inc's Family Patents

Acadia Pharms Inc drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 35.6% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Acadia Pharms Inc Drug List

Given below is the complete list of Acadia Pharms Inc's drugs and the patents protecting them.


1. Daybue

Daybue is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11827600 Crystalline forms of trofinetide 12 Jul, 2042
(17 years from now)
Active
US11370755 Compositions of trofinetide 03 Aug, 2040
(15 years from now)
Active
US9212204 Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid 27 Jan, 2032
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daybue's drug page


2. Nuplazid

Nuplazid is protected by 21 patents, out of which 11 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10449185 Formulations of pimavanserin 27 Aug, 2038
(13 years from now)
Active
US10646480 Formulations of pimavanserin 27 Aug, 2038
(13 years from now)
Active
US10849891 Formulations of pimavanserin 27 Aug, 2038
(13 years from now)
Active
US11452721 Formulations of pimavanserin 27 Aug, 2038
(13 years from now)
Active
US10517860 Combination of pimavanserin and cytochrome P450 modulators 23 Mar, 2037
(12 years from now)
Active
US10953000 Combination of pimavanserin and cytochrome P450 modulators 23 Mar, 2037
(12 years from now)
Active
US7601740 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 29 Apr, 2030
(5 years from now)
Active
US7732615 N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms 03 Jun, 2028
(3 years from now)
Active
US7659285 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 24 Aug, 2026
(1 year, 10 months from now)
Active
US7923564 Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms 26 Sep, 2025
(11 months from now)
Active
US10028944 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 15 Jan, 2024
(8 months ago)
Expired
US8618130 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 15 Jan, 2024
(8 months ago)
Expired
US8921393 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 15 Jan, 2024
(8 months ago)
Expired
US9566271 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases 15 Jan, 2024
(8 months ago)
Expired
US9765053 Methods of treatment using selective 5-HT2A inverse agonists 27 Jul, 2022
(2 years ago)
Expired
US7115634 4-aminopiperidine and their use as a medicine 06 Oct, 2021
(3 years ago)
Expired
US6756393 Azacyclic compounds 06 Mar, 2021
(3 years ago)
Expired
US6815458 Azacyclic compounds 06 Mar, 2021
(3 years ago)
Expired
US9296694 Azacyclic compounds 06 Mar, 2021
(3 years ago)
Expired
US7858789 Derivatives of 4-aminopiperidine and their use as a medicament 13 Dec, 2020
(3 years ago)
Expired
US8110574 Derivatives of 4-aminopiperidine and their use as a medicament 13 Dec, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nuplazid's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List